LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Chiusa

SettoreSettore sanitario

140.29 0.24

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

140.04

Massimo

141.94

Metriche Chiave

By Trading Economics

Entrata

394M

635M

Vendite

215M

2.6B

P/E

Media del settore

12.653

35.733

EPS

3.02

Margine di Profitto

23.995

Dipendenti

7,605

EBITDA

457M

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.72% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

442M

19B

Apertura precedente

140.05

Chiusura precedente

140.29

Notizie sul Sentiment di mercato

By Acuity

31%

69%

92 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Biogen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 set 2025, 09:30 UTC

Acquisizioni, Fusioni, Takeovers

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 set 2025, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

5 set 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

5 set 2025, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 set 2025, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 set 2025, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 set 2025, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 set 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 set 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 set 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 set 2025, 20:20 UTC

Utili

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 set 2025, 19:23 UTC

Discorsi di Mercato

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 set 2025, 19:22 UTC

Utili

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 set 2025, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 set 2025, 18:59 UTC

Utili

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 set 2025, 18:35 UTC

Discorsi di Mercato

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 set 2025, 17:25 UTC

Discorsi di Mercato

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 set 2025, 17:20 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 set 2025, 17:17 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 set 2025, 17:17 UTC

Discorsi di Mercato

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 set 2025, 17:03 UTC

Discorsi di Mercato

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 set 2025, 16:39 UTC

Acquisizioni, Fusioni, Takeovers

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 set 2025, 16:39 UTC

Acquisizioni, Fusioni, Takeovers

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 set 2025, 16:39 UTC

Acquisizioni, Fusioni, Takeovers

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 set 2025, 16:39 UTC

Acquisizioni, Fusioni, Takeovers

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 set 2025, 16:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

5 set 2025, 16:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

5 set 2025, 16:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 set 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

5 set 2025, 16:16 UTC

Utili

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Biogen Inc Previsione

Obiettivo di Prezzo

By TipRanks

20.72% in crescita

Previsioni per 12 mesi

Media 169.81 USD  20.72%

Alto 260 USD

Basso 118 USD

Basato su 26 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Biogen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

26 ratings

12

Acquista

14

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

118.15 / 121.17Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

92 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat